METABOLIC+ Bundle
The METABOLIC+ Bundle is a three-vial metabolic research stack: Tirzepatide 10 mg, AOD-9604 5 mg and Tesamorelin 10 mg — three independent metabolic research tools, at 10% off the individual vial prices.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, characterised in a 2018 Lancet trial[2]. AOD-9604 is a modified C-terminal lipolytic fragment (176-191) of human growth hormone[3]. Tesamorelin is a stabilised GHRH analogue studied in randomised metabolic trials[5].
Each vial is supplied as a lyophilized powder for reconstitution, and each compound has its own lot-specific third-party certificate of analysis, available on request. Findings above come from preclinical and clinical research on these molecules and are provided as scientific reference for laboratory research only.
Couldn't load pickup availability
Out of stock — get notified
Leave your email and we’ll let you know the moment it’s available again.
Need reconstitution solution? Don’t forget to add Bacteriostatic Water before checkout.
Metabolic Research Stack
Three Vials, One Research Focus
The METABOLIC+ Bundle assembles three metabolically focused research compounds. Tirzepatide is a dual GIP and GLP-1 receptor agonist, characterised in a 2018 Lancet trial[2]. AOD-9604 is a modified C-terminal fragment (176-191) of human growth hormone, studied as a synthetic lipolytic domain[3]. Tesamorelin is a stabilised GHRH analogue whose metabolic effects were characterised in a 2007 New England Journal of Medicine trial[5].
- Three metabolic research pathways in one set
- Tirzepatide — dual GIP/GLP-1 incretin signalling
- AOD-9604 — hGH fragment 176-191, lipolysis research
- Tesamorelin — GHRH analogue, visceral-fat research
- Lot-specific third-party COA for each compound
Inside the Bundle
What's in the Stack
The bundle ships as three separate lyophilized vials: Tirzepatide 10 mg, AOD-9604 5 mg and Tesamorelin 10 mg. The three compounds cover distinct arms of metabolic research: incretin-receptor signalling (tirzepatide, whose weight-related outcomes were reported in the SURMOUNT-1 trial[1]), growth-hormone-fragment lipolysis (AOD-9604[3]) and GHRH-axis signalling (tesamorelin[5]).
- Tirzepatide — 10 mg lyophilized vial
- AOD-9604 — 5 mg lyophilized vial
- Tesamorelin — 10 mg lyophilized vial
- Incretin + lipolysis + GHRH-axis research coverage
- 10% saving versus buying the three vials separately
Research Applications
Areas of Scientific Investigation
Each compound carries its own line of evidence: in clinical trials, tirzepatide produced substantial weight reduction in adults with obesity[1]; in obese-mouse studies, chronic treatment with the hGH C-terminal fragment increased fat oxidation and weight loss[4]; and tesamorelin reduced liver fat in a randomised trial in people with HIV[6]. No published study evaluates the three compounds in combination; researchers using them side by side are combining independent lines of evidence.
- Incretin-receptor and glucose-homeostasis research
- Lipolysis and fat-oxidation assays
- GHRH-axis and body-composition studies
- Energy-balance and appetite-signalling models
Understanding the Metabolic+ Stack: Mechanism of Action
Tirzepatide is structurally distinct from single-target incretin peptides: it activates both GLP-1 and GIP receptors. Its efficacy and safety as a dual agonist were characterised in a 2018 Lancet dose-ranging trial[2], and in the SURMOUNT-1 trial it produced substantial, dose-dependent weight reduction in adults with obesity[1].
AOD-9604 is a modified synthetic analogue of the C-terminal region (amino acids 176-191) of human growth hormone — the segment associated with hGH's lipolytic activity — without the whole hormone's growth-promoting signalling. It was characterised as a synthetic lipolytic domain in metabolic studies[3], and chronic treatment increased fat oxidation and weight loss in obese-mouse models[4].
Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone (GHRH). In randomised clinical trials it reduced visceral adipose tissue in patients with HIV-associated lipodystrophy[5] and reduced liver fat in a randomised, double-blind trial in people with HIV[6].
Together, the three vials cover three independent arms of metabolic research: incretin-receptor signalling, growth-hormone-fragment lipolysis and GHRH-axis stimulation. Each arm is supported by its own line of published evidence; no published study evaluates the combination itself. These materials are supplied strictly for laboratory research use.
Scientific Literature
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
- Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes. Lancet. 2018;392(10160):2180-2193.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8.
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-9.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830.
Packaged with care, shipped fast.
We’re a passionate team obsessed with quality, not margins.
- Company
- Price
- Purity
- Quantity
- Shipping
-
METABOLIC+ Bundle
-
Prime
Lab PeptidesTypical
Competitor -
$225.00$405.00
- ≥99%96%
- 3 vials3 vials
- Free 2-Day Shipping3-10 Business Day
-
